
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.

Date of Report: May 23, 2018
(Date of earliest event reported)

Oragenics, Inc.
(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-32188
(Commission
File Number)

59-3410522
(IRS Employer
Identification Number)

4902 Eisenhower Boulevard, Suite 125
Tampa, FL
(Address of principal executive offices)

33634
(Zip Code)

813-286-7900
(Registrant's telephone number, including area code)

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.***Issuance of Patent***

On May 23, 2018, Oragenics, Inc. (the “Company”) announced that the United States Patent and Trademark Office (USPTO) has granted Oragenics and The Texas A&M University System U.S. Patent No. 9,964,488 titled, “Variants of the Lantibiotic MU1140 and Other Lantibiotics with Improved Pharmacological Properties and Structural Features.”

The patent covers the unique variants of the lantibiotic 1140 (MU1140) and other lantibiotics with improved pharmacological properties and structural features as well as the methods of using these compositions to treat and prevent infections, diseases, and colonization by one or more types of bacteria.

A copy of the press release announcing these events is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Pro-forma Shareholders' Equity

The Company also announced today its Total Shareholders' Equity as of March 31, 2018 and its *pro forma* Shareholders' Equity as of March 31, 2018, which incorporates the previously announced closing of the Company's registered direct offering of 900,000 shares of its common stock at a price of \$2.00 per share and concurrent private placement of 900,000 warrants at an exercise price of \$2.00 per share on April 6, 2018, respectively (the “Offering”). As set forth in the Oragenics, Inc. March 31, 2018, Form 10-Q, filed on May 15, 2018, the Company reported \$4,315,236 in Total Shareholders' Equity. After adjusting for the proceeds from the sale of securities from the registered direct offering, the Company is announcing Total Shareholders' Equity of approximately \$6.1 million, on a pro forma basis, as of March 31, 2018.

The following table sets forth the Company's Total Shareholders' Equity position as of March 31, 2018, as adjusted on a *pro forma* basis to reflect the Offering:

Oragenics, Inc.
Pro Forma Shareholder's Equity
(U.S. dollars)

Total Shareholders' Equity as of March 31, 2018	\$ 4,315,236
Proceeds from April 6, 2018 Offering*	<u>1,800,000</u>
Pro forma Total Shareholders' Equity, as of March 31, 2018, as adjusted*	<u>\$ 6,115,236</u>

* Not reviewed by independent auditors

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit</u> <u>No.</u>	<u>Description</u>
99.1	<u>Press Release dated May 23, 2018.</u>

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 25th day of May, 2018.

ORAGENICS, INC.
(Registrant)

BY: /s/ Michael Sullivan
Michael Sullivan
Chief Financial Officer

Orogenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140

May 23, 2018 02:00 PM Eastern Daylight Time

TAMPA, Fla.—(BUSINESS WIRE)—Orogenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted Orogenics and The Texas A&M University System U.S. Patent No. 9,964,488 titled, “Variants of the Lantibiotic MU1140 and Other Lantibiotics with Improved Pharmacological Properties and Structural Features.”

Among other things, the patent covers the unique variants of the lantibiotic 1140 (MU1140) and other lantibiotics with improved pharmacological properties and structural features as well as the methods of using these compositions to treat and prevent infections, diseases, and colonization by one or more types of bacteria.

“In recent years, antibiotic resistant bacteria have been on the rise, affecting millions of people worldwide and resulting in an increasingly large burden on the healthcare system. Lantibiotics serve as an important class of antibiotics with the potential to serve in the treatment of problematic infections caused by Gram-positive bacteria, while also potentially limiting the development of drug resistance,” Alan Joslyn, chief executive officer and president of Orogenics, said. “This patent provides broad protection for unique variants of MU1140 and other lantibiotics in our library that will enter IND-enabling studies for the treatment of antibiotic resistant bacteria.”

James Smith, associate professor in the Department of Biology at Texas A&M University, said, “Healthcare-associated infections caused by multi-drug resistant pathogens have become particularly worrisome. Through our collaborative work, we are pleased that the granting of this patent will support the continued development of novel lantibiotics. We are hopeful that we are on a path towards new antibiotic treatments that have the potential to target this critical, unmet need in the medical community.”

About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc., has established two exclusive worldwide channel collaborations with Intrexon Corporation (NYSE: XON) and its subsidiaries. The collaborations allows Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat and esophagus.

For more information about Oragenics, please visit www.oragenics.com.

About the Department of Biology at Texas A&M University

The Department of Biology is responsible for research and teaching within the vast disciplines of the biological sciences, from molecular cell biology to ecology and evolutionary biology. Our faculty performs cutting-edge research in a wide array of biological sciences in the laboratory and in the field. Our graduate research programs prepare scientists for careers in academia, industry and government, and enhance our understanding of the central role of biological systems in the global environment. Our undergraduate students gain a firm foundation in modern biological sciences to prepare them for a multitude of careers that depend on a solid understanding of biology.

For more information about the Department of Biology at Texas A&M University, please visit <http://www.bio.tamu.edu/>.

About Research at Texas A&M University: As one of the world's leading research institutions, Texas A&M is at the forefront in making significant contributions to scholarship and discovery, including that of science and technology. Research conducted at Texas A&M represented annual expenditures of more than \$905.4 million in fiscal year 2017. Texas A&M ranked in the top 20 of the National Science Foundation's Higher Education Research and Development survey (2016), based on expenditures of more than \$892.7 million in fiscal year 2016. Texas A&M's research creates new knowledge that provides basic, fundamental and applied contributions resulting, in many cases, in economic benefits to the state, nation and world. To learn more, visit <http://research.tamu.edu>.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management's current views with respect to future events and performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These

factors include, but are not limited to, whether the reverse stock split will be beneficial to the Company and its shareholders, any inability to meet the NYSE American continued listing standards in the future for any reason, and those other factors described in our filings with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.

Contacts

Orogenics, Inc.

Corporate:

Michael Sullivan, 813-286-7900

chief financial officer

msullivan@orogenics.com

or

Investor/Media Relations:

The Ruth Group

Tram Bui, 646-536-7035

tbui@theruthgroup.com